Shares of Mazor Robotics Ltd – (NASDAQ:MZOR) saw unusually-strong trading volume on Monday . Approximately 192,602 shares changed hands during mid-day trading, an increase of 14% from the previous session’s volume of 168,255 shares.The stock last traded at $22.91 and had previously closed at $23.20.

A number of analysts have commented on MZOR shares. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics Ltd – in a research report on Tuesday, May 10th. Wells Fargo & Co. upgraded Mazor Robotics Ltd – from a “market perform” rating to an “outperform” rating in a research report on Thursday, May 19th. Zacks Investment Research upgraded Mazor Robotics Ltd – from a “sell” rating to a “hold” rating in a research report on Thursday, May 19th. Sterne Agee CRT downgraded Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 31st. Finally, Standpoint Research started coverage on Mazor Robotics Ltd – in a research report on Friday, July 8th. They issued a “buy” rating and a $30.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $25.00.

The company has a 50-day moving average of $20.01 and a 200-day moving average of $13.91. The company’s market capitalization is $485.91 million.

Mazor Robotics Ltd – (NASDAQ:MZOR) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.02. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The firm earned $8.30 million during the quarter, compared to the consensus estimate of $8.51 million. The firm’s revenue was up 6.4% on a year-over-year basis. Analysts forecast that Mazor Robotics Ltd – will post ($0.55) earnings per share for the current fiscal year.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.